Precision Biosciences (DTIL) Cash & Current Investments (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Cash & Current Investments data on file, last reported at $101.2 million in Q1 2026.

• Quarterly Cash & Current Investments rose 31.03% year-over-year to $101.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $101.2 million (up 31.03% YoY) and the FY2025 annual result came in at $115.6 million, up 33.92% from the prior year.
• Cash & Current Investments slipped to $101.2 million in Q1 2026 per DTIL's latest filing, from $115.6 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $212.1 million in Q3 2022 and bottomed at $44.9 million in Q3 2025.
• The 5-year median for Cash & Current Investments is $116.7 million (2023), against an average of $122.8 million.
• The widest annual swing landed in 2023, when Cash & Current Investments surged 36.06%; it then sank 55.66% in 2025.
• Tracing DTIL's Cash & Current Investments over 5 years: stood at $189.6 million in 2022, then sank by 38.45% to $116.7 million in 2023, then slipped by 26.03% to $86.3 million in 2024, then jumped by 33.92% to $115.6 million in 2025, then dropped by 12.46% to $101.2 million in 2026.
• Per Business Quant, the three latest DTIL Cash & Current Investments figures stand at $101.2 million (Q1 2026), $115.6 million (Q4 2025), and $44.9 million (Q3 2025).

Peer Comparison